Gilead Sciences GILD
- Market cap
- $212.5B
- PE
- n/m
- a loss over the last year
- Forward PE
- 19.8×
- 10y median 10.5×
- Price to sales
- 6.9×
- EV/EBIT
- 24.6×
- Revenue, 12 months
- $31B
- +7% on a year ago
- Net margin
- −12.5%
- Free cash flow yield
- n/m
- Q3 FY26 missing
Gilead Sciences trades at 6.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $31B over the last twelve months, up 7% on a year earlier with a −12% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.1B−4% | $6.7B+5% | $7B+5% | $7.5B+7% | $7.6B+6% | $6.7B−0% | $7.1B+2% | $7.8B+3% | $7.9B+5% | $7B+4% | $7.8B+10% | $8.3B+7% | |
| Cost of revenue | $2.1B+50% | $1.6B+11% | $1.5B+7% | $1.6B+1% | $1.6B−24% | $1.5B−1% | $1.5B−3% | $1.6B−0% | $1.6B+3% | $1.4B−6% | $1.6B+5% | $1.6B+0% |
| Gross profit | $5B−16% | $5.1B+4% | $5.4B+5% | $6B+9% | $6B+19% | $5.1B−0% | $5.6B+3% | $6.2B+4% | $6.3B+5% | $5.5B+8% | $6.2B+12% | n/a |
| R&D | $1.4B−9% | $1.5B+5% | $1.4B−4% | $1.4B−4% | $1.6B+17% | $1.4B−9% | $1.5B+10% | $1.3B−4% | $1.6B−4% | $1.4B−1% | $1.8B+18% | $1.6B+20% |
| SG&A | $1.6B−20% | $1.4B+4% | $1.4B−26% | $1.4B+9% | $1.9B+19% | $1.3B−9% | $1.4B−1% | $1.4B−5% | $1.8B−6% | $1.5B+15% | $1.9B+41% | $1.6B+21% |
| $1.6B−29% | −$4.3B | $2.6B+59% | $888M−66% | $2.5B+52% | $2.2B | $2.5B−6% | $3.3B+275% | $2B−19% | $2.6B+16% | −$10.4B | $3.5B+4% | |
| Interest expense | $252M+12% | $254M+10% | $237M+3% | $238M+3% | $249M−1% | $260M+2% | $254M+7% | $256M+8% | $255M+2% | $240M−8% | $247M−3% | n/a |
| Pre-tax income | $1.7B−19% | −$4.5B | $2.1B+29% | $956M−59% | $2.2B+31% | $1.6B | $2.4B+18% | $3.6B+281% | $2.1B−4% | $2.6B+57% | −$10.3B | $3.1B−16% |
| $237M−41% | −$315M | $438M−20% | −$297M | $385M+62% | $334M | $468M+7% | $589M | −$105M | $559M+67% | $242M−48% | n/a | |
| Net income | $1.4B−13% | −$4.2B | $1.6B+54% | $1.3B−43% | $1.8B+25% | $1.3B | $2B+21% | $3.1B+144% | $2.2B+22% | $2B+54% | −$10.5B | $2.4B−20% |
| $1.14−12% | −$3.34 | $1.29+55% | $1.00−42% | $1.42+25% | $1.04 | $1.56+21% | $2.43+143% | $1.74+23% | $1.61+55% | −$8.45 | $1.94−20% | |
| 1.3B−1% | 1.2B−1% | 1.3B−1% | 1.3B−0% | 1.3B+0% | 1.3B+1% | 1.3B+0% | 1.3B+0% | 1.3B−1% | 1.3B−0% | 1.2B−1% | 1.3B−0% |
Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: 4 periods, Q4 FY08 to Q2 FY12: quarter's net income to common over its shares, to the cent. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 9 periods, Q4 FY08 to Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY12: share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x2). Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $8.3B | $8.3B to $8.4B | $1.39 | $0.78 to $1.64 | 11 |
| Q1 FY27 | $7.5B | $7.2B to $8B | $2.17 | $2.09 to $2.25 | 4 |
| Q2 FY27 | $8.2B | $8B to $8.4B | $2.46 | $2.40 to $2.55 | 1 |
| Q3 FY27 | $8.6B | $8.4B to $8.8B | $2.63 | $2.56 to $2.72 | 1 |
| Q4 FY27 | $9.1B | $8.9B to $9.4B | $2.77 | $2.69 to $2.86 | 1 |
| Q1 FY28 | $7.7B | $7.5B to $7.9B | $2.06 | $2.00 to $2.13 | 2 |
| Q2 FY28 | $8.2B | $8B to $8.4B | $2.35 | $2.28 to $2.43 | 2 |
| Q3 FY28 | $8.4B | $8.2B to $8.7B | $2.45 | $2.38 to $2.54 | 2 |
Peers
Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GILDGilead Sciences | $212.5B | n/m | 18.8× | 19.8× | 6.9× | +7% | −12.5% |
| AMGNAmgen | $252.3B | 29.0× | 21.2× | 19.8× | 6.6× | +9% | 23.0% |
| PFEPfizer | $176B | 40.6× | 15.8× | 11.2× | 2.8× | −0% | 6.8% |
| BMYBristol-Myers Squibb | $128.7B | 14.0× | 19.9× | 9.8× | 2.6× | +4% | 18.5% |
| MRKMerck | $359.5B | 150× | 25.0× | 17.2× | 5.3× | +5% | 3.6% |
| ABBVAbbVie | $511.6B | 49.8× | 27.9× | 18.3× | 7.7× | +11% | 15.7% |
| JNJJohnson & Johnson | $650.2B | 40.9× | 24.3× | 23.9× | 6.5× | +8% | n/m |
| BIIBBiogen | $37B | 44.3× | 16.2× | 19.0× | 3.7× | +0% | 8.3% |
| LLYEli Lilly and | $1.3T | 46.5× | 41.6× | 30.9× | 15.6× | +46% | 31.9% |
| Peer median | $305.9B | 42.6× | 22.7× | 18.7× | 5.9× | +6% | 15.7% |
Investors who own it
Investors we follow who held Gilead Sciences at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Gilead Sciences
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .